Envoy Medical (NASDAQ:COCH) Trading Up 9.4% – Still a Buy?

Envoy Medical, Inc. (NASDAQ:COCH) shares traded up 9.4% during mid-day trading on Tuesday . The company traded as high as $0.79 and last traded at $0.7587. Approximately 1,165,296 shares changed hands during trading, an increase of 60% from the average session volume of 729,197 shares. The stock had previously closed at $0.6937.

More Envoy Medical News

Here are the key news stories impacting Envoy Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Envoy Medical and maintained a $2.50 target price, which supports investor optimism about future upside. Benzinga article
• Neutral Sentiment: The firm’s new forecasts call for continued losses in 2027, with EPS estimates of about $(0.06) in Q1 and Q2, $(0.05) in Q3, $(0.03) in Q4, and $(0.19) for FY2027, which suggests improvement but not profitability yet.
• Neutral Sentiment: Market chatter also noted the stock was trading higher recently, likely reflecting the analyst endorsement and bullish price target rather than any new operating news. American Banking News article

Analysts Set New Price Targets

A number of research analysts have weighed in on COCH shares. HC Wainwright reaffirmed a “buy” rating and set a $2.50 target price on shares of Envoy Medical in a report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a report on Friday, April 24th. Finally, Zacks Research raised shares of Envoy Medical to a “hold” rating in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $2.50.

Envoy Medical Stock Up 5.1%

The firm has a market capitalization of $58.44 million, a PE ratio of -0.75 and a beta of 1.88. The company has a 50-day moving average of $0.69 and a 200 day moving average of $0.68.

Envoy Medical (NASDAQ:COCH) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, equities analysts anticipate that Envoy Medical, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Envoy Medical

Several hedge funds have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new position in shares of Envoy Medical in the 3rd quarter worth $60,000. Geode Capital Management LLC lifted its holdings in shares of Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after acquiring an additional 51,813 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of Envoy Medical during the 1st quarter worth $276,000. Finally, DSG Capital Advisors LLC purchased a new position in Envoy Medical in the first quarter worth $416,000. 8.59% of the stock is currently owned by institutional investors.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.